Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

“CI what is your educated guess or opinion on wh

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153763
(Total Views: 664)
Posted On: 07/15/2020 8:52:41 PM
Avatar
Posted By: ClosetInvestor
Re: Longestyard #43173
“CI what is your educated guess or opinion on what the forthcoming data results will show? As far as being good to not good or interpreted as not good? 50/50 good/ng, 60/40 good/ng? What are you thinking personally?”

IMO, I believe that data from the severe trial will be clear: leronlimab statistically and significantly reduces the death rate in severe patients when compared to placebo. My belief is based on the data from the initial EINDs and the fact that outside of the first 11 patients, none of the other 54 died after receiving leronlimab (NP stated this during a CC or interview, but I can’t recall which one). Of course we don’t know how severe each EIND patient was, but I don’t think CYDY was filling EINDs for patients with a minimal cough and fever.

In regards to the M2M trial, I’m mixed. The primary endpoints aren’t as clear cut, but the secondary are, such as hospitalization rate, length of hospitalization, ventilation rate, length of ventilation and death rate. I don’t know if leronlimab will be approved on just the primary endpoints (i.e. patients feel better) but instead on the big issues that COVID19 is causing: hospitalizations and deaths. Also, the small 86 person trial concerns me and I’m unsure why the FDA approves a 75 person M2M and a 395 patient severe trial. The M2M should’ve at least had 150-200 patients. I suspect the data will be good but the FDA will ask for a larger trial.


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us